EPA:ADOC - FR0011184241 - Common Stock
The current stock price of ADOC.PA is 8.19 EUR. In the past month the price increased by 24.66%. In the past year, price increased by 50%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 20.04 | 321.87B | ||
1ABBV.MI | ABBVIE INC | 19.56 | 314.07B | ||
AMG.DE | AMGEN INC | 12.96 | 130.61B | ||
1GILD.MI | GILEAD SCIENCES INC | 14.78 | 122.10B | ||
GIS.DE | GILEAD SCIENCES INC | 14.55 | 119.87B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 23.38 | 87.15B | ||
ARGX.BR | ARGENX SE | 82.38 | 37.36B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.61B | ||
IDP.DE | BIOGEN INC | 8.82 | 17.76B | ||
0QF.DE | MODERNA INC | N/A | 7.98B | ||
1MRNA.MI | MODERNA INC | N/A | 7.96B | ||
1EXAS.MI | EXACT SCIENCES CORP | N/A | 7.29B |
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 77 full-time employees. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
ADOCIA SAS
115 avenue Lacassagne
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 76
Phone: 33472610610
The current stock price of ADOC.PA is 8.19 EUR. The price increased by 0.86% in the last trading session.
The exchange symbol of ADOCIA SAS is ADOC and it is listed on the Euronext Paris - Matif exchange.
ADOC.PA stock is listed on the Euronext Paris - Matif exchange.
8 analysts have analysed ADOC.PA and the average price target is 10.2 EUR. This implies a price increase of 24.54% is expected in the next year compared to the current price of 8.19. Check the ADOCIA SAS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ADOCIA SAS (ADOC.PA) has a market capitalization of 149.71M EUR. This makes ADOC.PA a Micro Cap stock.
ADOCIA SAS (ADOC.PA) currently has 76 employees.
ADOCIA SAS (ADOC.PA) has a support level at 8.18 and a resistance level at 8.91. Check the full technical report for a detailed analysis of ADOC.PA support and resistance levels.
The Revenue of ADOCIA SAS (ADOC.PA) is expected to decline by -53.12% in the next year. Check the estimates tab for more information on the ADOC.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ADOC.PA does not pay a dividend.
ADOCIA SAS (ADOC.PA) will report earnings on 2025-09-25.
ADOCIA SAS (ADOC.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.65).
ChartMill assigns a technical rating of 9 / 10 to ADOC.PA. When comparing the yearly performance of all stocks, ADOC.PA is one of the better performing stocks in the market, outperforming 98.38% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to ADOC.PA. ADOC.PA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ADOC.PA reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS increased by 66.43% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -34.5% | ||
ROE | N/A | ||
Debt/Equity | N/A |
8 analysts have analysed ADOC.PA and the average price target is 10.2 EUR. This implies a price increase of 24.54% is expected in the next year compared to the current price of 8.19.
For the next year, analysts expect an EPS growth of -69.76% and a revenue growth -53.12% for ADOC.PA